Hyperpolarized $^{13}$C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas

Kayvan R. Keshari$^{1,a}$, Renuka Sriram$^1$, Bertram L. Koelsch$^2$, Mark Van Criekinge$^1$, David M. Wilson$^1$, John Kurhanewicz$^{1,2}$, Zhen J. Wang$^1$

$^1$Department of Radiology and Biomedical Imaging
University of California, San Francisco
San Francisco, CA 94143, USA

$^2$UC Berkeley – UCSF Graduate Program in Bioengineering
San Francisco, CA 94143, USA

$^a$Correspondence and Reprint request:
Kayvan R. Keshari, Ph.D.
Department of Radiology and Biomedical Imaging
University of California, San Francisco
1700 4th St.
Byers Hall 203
San Francisco, CA 94158
Phone: (415) 514-9717
Fax: (415) 514-9711
kayvan.keshari@ucsf.edu

Running title: HP pyruvate MR in renal cell carcinoma cells

Key words: metabolic flux, monocarboxylate transporter, lactate efflux, bioreactor, magnetic resonance spectroscopy

Grant support: This work was supported by NIH P41EB013598 (to JK), R01CA166766 (to DMW), K99EB014328 (to KRK), Department of Defense Peer Reviewed Cancer Research Concept Award (to ZJW), Radiological Society of North America Scholar grant (to ZJW).
HP pyruvate MR in renal cell carcinoma cells

No Conflict of Interest

Word count: 4994; Figure numbers: 6
HP pyruvate MR in renal cell carcinoma cells

Abstract
Renal cell carcinomas (RCCs) are a heterogeneous group of tumors with a wide range of aggressiveness. Noninvasive methods to confidently predict the tumor biological behavior and select appropriate treatment are lacking. Here, we investigate the dynamic metabolic flux in living RCC cells using hyperpolarized $^{13}$C-pyruvate magnetic resonance spectroscopy (MRS) combined with a bioreactor platform, and interrogated the biochemical basis of the MRS data with respect to cancer aggressiveness. RCC cells have significantly higher pyruvate-to-lactate flux than the normal renal tubule cells. Furthermore, a key feature distinguishing the localized from the metastatic RCC cells is the lactate efflux rate, mediated by the monocarboxylate transporter 4 (MCT4). The metastatic RCC cells have significantly higher MCT4 expression and corresponding higher lactate efflux, which is essential for maintaining a high rate of glycolysis. We show that such differential cellular transporter expression and associated metabolic phenotype can be noninvasively assessed via real-time monitoring of hyperpolarized $^{13}$C-pyruvate-to-lactate flux.
Introduction

The incidence of renal tumors, both malignant renal cell carcinomas (RCCs) and benign renal tumors, has risen significantly in the last 20 years (1). In the case of renal tumors, biopsies are not routinely done, due to the risk of hemorrhage and high likelihood of indeterminate histology (2, 3). Treatment selection is thus heavily reliant on non-invasive imaging assessment of tumor masses. However, there are significant limitations to the current imaging methods for renal tumor characterization. It is increasingly recognized that RCCs are a heterogeneous group of tumors with a wide range of biological aggressiveness (4, 5). Emerging active surveillance data have shown that a significant percentage of small RCCs (< 4cm) are indolent with low metastatic risk, and patients may be over-treated if all such RCCs are surgically removed (5, 6). On the other hand, 20-40% of patients undergoing nephrectomies for clinically localized RCCs develop metastases with poor outcome (7). Unfortunately, current imaging methods cannot reliably predict the risks of progression from localized RCC to metastatic disease (8). Furthermore, certain benign renal tumors are difficult to distinguish from RCCs by imaging (9). This diagnostic challenge has resulted in the unnecessary resection of many benign renal tumors, which constitute 20% of all renal tumors <4cm, with the associated surgical risks and potential loss of renal function (10). Therefore, new imaging methods are needed to predict the biological behavior of renal tumors and select appropriate treatment.

The unique metabolism of cancer cells is central to their malignant behavior. For example, a common property of cancers is altered glucose metabolism with elevated glycolysis and lactate production in the presence of oxygen (11, 12). Increased glycolysis facilitates the uptake and incorporation of nutrients and biomass needed for cell proliferation in cancers (13, 14), and acidifies the extracellular microenvironment promoting invasion of neighboring tissue and metastasis (15). A number of genomics and proteomics studies have demonstrated increased metabolism to lactate in RCCs (16-19). Specifically, proteomic analysis of RCC tissues and metabolic profiling of serum samples revealed increased levels of glycolytic...
enzymes in RCC tissues and higher lactate in the serum of RCC patients (19). Metastatic RCCs have also demonstrated a bio-energetic shift toward aerobic glycolysis and lactate production (18). These studies provide the rationale for metabolic imaging of glycolysis as a non-invasive means to characterize renal tumor aggressiveness.

Hyperpolarized (HP) $^{13}$C MR is a new molecular imaging technique that allows rapid and noninvasive monitoring of dynamic pathway-specific metabolic and physiological processes. Hyperpolarization, achieved through the dynamic nuclear polarization (DNP) technique (20), can provide dramatic gains in sensitivity (> 10,000-fold increase) for imaging $^{13}$C-labeled biomolecules. The HP $^{13}$C-probes can be injected into living systems, and their metabolism can be observed in real-time by chemical shift. The most commonly used HP $^{13}$C probe is $^{13}$C-pyruvate, which is at the juncture of several important energy and biosynthetic pathways. For example, pyruvate may be converted to lactate in glycolysis, to acetyl-CoA to support the tricarboxylic acid (TCA) cycle, or to alanine via transamination for protein synthesis. HP $^{13}$C-pyruvate MR has already been applied to the detection of the presence (21-25) and progression (26, 27) of a number of cancers. The metabolic changes seen in RCCs suggest that HP $^{13}$C-pyruvate will also be an excellent probe to interrogate these tumors noninvasively.

In this work, we compared the pyruvate metabolism of immortalized cells derived from human renal proximal tubules (the origin of most human RCCs), a localized human RCC, and a metastatic human RCC, with the goal of identifying clinically translatable HP biomarkers of renal tumor aggressiveness. After evaluating the steady-state metabolism of these cells, we assessed the dynamic HP pyruvate-to-lactate flux using a MR compatible bioreactor platform that provides a controlled and physiological setting for the cells (28). By monitoring the real time metabolic flux using HP MR, we showed that RCC cells have significantly higher pyruvate-to-lactate flux than the normal renal proximal tubule cells. Furthermore, we showed that cells derived from the metastatic RCC have more rapid export of lactate to the extracellular space compared to the cells derived from the localized RCC, and that these differences are likely mediated by the
HP pyruvate MR in renal cell carcinoma cells

differential expression of monocarboxylate transporter 4 (MCT4). These results suggest that using HP $^{13}$C-pyruvate to assess lactate production and export has the potential to improve the non-invasive characterization of renal tumors.

Materials and Methods

Cell lines

HK-2 is an immortalized proximal tubule epithelial cell line from normal adult human kidney (29), and was obtained from American Type Culture Collection (ATCC, Virginia; obtained June, 2010; authentication performed at ATCC was via Short Tandem Repeat (STR) Profiling). UMRC6 cells are representative of localized human clear cell renal cell carcinoma (30), and were a gift from Dr. Bart Grossman (MD Anderson Cancer Center; obtained January, 2010; authenticated using STR Profiling, October 2012). UOK262 cells are derived from a metastasis of the highly aggressive hereditary leiomyomatosis renal cell carcinoma (HLRCC), which is characterized by mutation of the TCA cycle enzyme fumarate hydratase (FH) (31). UOK262 cells were a gift from Dr. W. Marston Linehan (National Cancer Institute; obtained May, 2010; authenticated using STR Profiling, October 2012). All cells were grown in Dulbeco’s Modified Eagle’s medium (DMEM) with 4.5g/L glucose. The cells were passaged serially and were used for assays and MR experiments between passages 2-10 and at 60-80% confluency.

$^1$H NMR experiments

Cells were plated on 150-cm$^2$ coated petri dishes (Fisher Scientific) and incubated for 24-hours in DMEM media supplemented with [1-$^{13}$C] glucose, or for 2-hours in DMEM media supplemented with [3-$^{13}$C] pyruvate (Cambridge Isotope Labs, MA). At the end of incubation, an aliquot of medium was collected, and cells were extracted in ice-cold methanol (32). The cell extracts were reconstituted in D$_2$O with known amounts of trimethyl silyl pentanoate (TSP) for internal reference. The extracts were measured on Bruker Advance III 800MHz equipped with a
HP pyruvate MR in renal cell carcinoma cells

cryo-cooled triple resonance probe. High-resolution water-suppressed proton spectra were obtained with a repetition time of 12s and 64 averages. The metabolite peak areas were quantified against the known TSP peak area.

Hyperpolarized [1-\textsuperscript{13}C] pyruvate MR Bioreactor experiment

Cells were electrostatically encapsulated into 2.5% weight/volume alginate microspheres as previously described (28, 33), and then loaded into a MR-compatible bioreactor. Approximately 800\textmu L of microspheres were perfused in the bioreactor with DMEM H-21 media at a flow rate of 2.5mL/min. For the flow rate modulation bioreactor experiments, the flow rate was changed to either 1.3mL/min or 3.8mL/min for the duration of the hyperpolarized scans. The media was kept at 37\textdegree C with water-jacketed perfusion lines and was maintained at 95% air/5% CO\textsubscript{2} via gas exchanger. All bioreactor studies were performed on a 500MHz Varian Inova (Agilent Technologies, CA) with a 10mm, triple-tune, direct-detect, broadband probe at 37\textdegree C. For the hyperpolarized \textsuperscript{13}C-pyruvate studies, 2.5\textmu L of 14.2M \textsuperscript{13}C-pyruvate mixed with 15mM of the trityl radical (GE Healthcare) was polarized on a Hypersense polarizer (Oxford Instruments, UK). This was followed by dissolution in 5mL of 50mM phosphate buffer. 1 mL of the resulting 7.5mM HP pyruvate solution was injected into the bioreactor containing the microspheres. Hyperpolarized \textsuperscript{13}C MR data were acquired dynamically with a 10\textdegree flip-angle, pulse repetition time of 3s and for a duration of 300s. \textsuperscript{31}P spectra (repetition time 3s, 1024 averages, 90\textdegree flip-angle) were acquired before and after each hyperpolarized study to assess cell viability.

Cell number determination for bioreactor experiments

Moles of ATP per cell for each cell line were measured using CellTiter-Glo luminescent cell viability assay and Veritas Luminometer (Promega, WI). Moles of ATP corresponding to the \textbeta-NTP peak area on \textsuperscript{31}P spectra were determined using a \textsuperscript{31}P calibration curve. The number of
cells in each bioreactor experiment was then calculated by dividing the moles of ATP approximated from β-NTP peak by the moles of ATP per cell as measured by the luminescent assay.

**mRNA expression and enzyme activity assay**

Total RNA was purified from cells using RNeasy procedure kit (Qiagen, USA), and reverse transcribed using iScript cDNA Synthesis kit (BioRad Laboratories, CA). PCR was conducted in triplicate for the lactate dehydrogenase α (LDH-α) and the monocarboxylate transporters 1 and 4 (Hs00161826_m1, Hs00358829_m1) on the ABI 7900HT (Applied Biosystems, CA). Cyclophilin and beta Actin (Applied Biosystems, CA) were used as control, and the relative fold difference was calculated for each primer/probe combination.

LDH activity of cell lysates was measured spectrophotometrically by quantifying the linear decrease in nicotinamide adenine dinucleotide (NADH) absorbance at varying pyruvate concentrations at 339 nm using a microplate reader (Tecan Group Ltd., Switzerland). The maximum velocity (Vmax) and the Michaelis-Menten constant (Km) were estimated using the Lineweaver- Burke plot.

**Data analysis**

The hyperpolarized pyruvate-to-lactate flux was calculated using a previously published model (28). The pyruvate-to-lactate flux was normalized by the number of cells in each bioreactor study and the injected amount of hyperpolarized pyruvate. $^{31}$P metabolite peaks were integrated and normalized by the number of cells to determine the concentration of phosphocholine (PC), glycerophosphocholine (GPC) and β nucleoside triphosphates (β-NTP). Resonances were corrected for their respective $^{31}$P T₁ relaxation times (Table S2). One way analysis of variance (ANOVA) was used to assess the difference between the 3 groups with
HP pyruvate MR in renal cell carcinoma cells

Tukey-Kramer HSD post-hoc tests using statistical software package JMP (SAS Institute, NC, USA). All values are reported as mean ± standard error.

Results

$^1$H MRS demonstrates steady-state metabolite concentrations that reflect increased glycolysis and truncated tricarboxylic acid (TCA) cycle in metastatic UOK262 cells

We first utilized $^1$H MR spectroscopy (MRS) to interrogate the steady-state metabolite concentrations in HK2, UMRC6 and UOK262 cells. HK2 cells are derived from human renal proximal tubule cells (doubling time = 72-96 hours) (29). UMRC6 cells (doubling time = 43 hours) originate from a localized human clear cell RCC (30). Lastly, UOK262 cells were isolated from a metastasis of hereditary leiomyomatosis renal cell carcinoma (HLRCC) (doubling time = 23 hours) (31). HLRCC is an aggressive RCC characterized by mutation of the TCA cycle enzyme fumarate hydratase (FH). UOK262 cells therefore have markedly reduced oxidative phosphorylation and are highly glycolytic (31). Figure 1a illustrates the biochemical scheme of glycolysis and TCA cycle. Figure 1b shows the major steady-state intracellular metabolite concentrations, as measured by $^1$H MRS, in the 3 cell lines. We found that the steady-state lactate concentration was significantly higher in the UOK262 cells compared to the UMRC6 or HK2 cells (both P<0.05). The increased steady-state lactate in the UOK262 cells is consistent with the FH mutation, which sharply attenuates the mitochondrial TCA cycle and concomitantly drives glycolysis for energy production (31).

The alanine concentration was lower in the two RCC cell lines compared to the HK2 cells, likely due to increased flux of pyruvate to lactate. We also found significantly increased glutamate and decreased aspartate concentration in the UOK262 cells compared to the other 2 cell lines. Glutamate is reversibly formed from $\alpha$-ketoglutarate, a TCA cycle intermediate proximal to fumarate. Aspartate is formed reversibly from oxaloacetate, a TCA intermediate distal to fumarate. In the UOK262 cells, the increased steady state glutamate and reduced
HP pyruvate MR in renal cell carcinoma cells

aspartate are consistent with truncation of TCA cycle metabolism beyond fumarate, due to the FH mutation. The concentration of glycerophosphocholine (GPC), an abundant renal osmolyte (34), was similar among the 3 cell lines. Interestingly, we found that phosphocholine (PC) was significantly higher in the UMRC6 cells than the UOK262 cells. While PC has been used as a biomarker of tumor proliferation and aggressiveness in other types of cancers (35, 36), the levels of PC did not correlate with aggressiveness in the RCC cell lines in our study. PC is converted from choline by the enzyme choline kinase α (CHKA) in the phosphatidylcholine synthesis (Kennedy) pathway. A recent study reported that CHKA forms a complex with epidermal growth factor receptor (EGFR) in a c-Src-dependent manner, and functions cooperatively with EGFR and c-Src in regulating pathways critical to cell proliferation (37). Such required functional interaction among the three enzymes for cancer cell proliferation may in part explain the lack of direct correlation between the PC levels and proliferation rates / aggressiveness of the two RCC cell lines in our study.

24-hour labeling of cells with [1-13C] glucose or [3-13C] pyruvate in 2D cell cultures demonstrates increased flux to lactate in the metastatic UOK262 cells

To further characterize glycolysis and lactate production in the RCC cells, we investigated the flux from labeled [1-13C] glucose to lactate in 2D cell cultures following 24-hour incubation. Figure 2a shows the scheme of 13C labeled carbon atom transitions used to detect glucose metabolism to lactate. Glucose, the primary fuel for energy in cells, is taken up primarily via the glucose transporter 1 (GLUT1), and is converted to pyruvate and then lactate during glycolysis. Lactate is preferentially exported out of the cells via the monocarboxylate transporter 4 (MCT4) (38). Figure 2b and 2c demonstrate representative MR spectra of metabolites in the culture medium and intracellular compartment, respectively, of UOK262 cells following 24 hour labeling with [1-13C] glucose. Figure 2d and 2e show the concentrations of 13C labeled lactate in the medium and the intracellular compartment, respectively, of the 3 cell lines following
incubation with [1-13C] glucose. After 24 hour of incubation with [1-13C] glucose, 99% of lactate was found in the extracellular medium. The concentration of 13C lactate in the medium increased progressively from HK2 to UMRC6 to UOK262 cells, with the lactate concentration being nearly three-fold higher in the medium of UOK262 cells compared to that of the HK2 cells. The fractional enrichment (FE) of lactate was defined as the 13C labeled lactate / (13C labeled lactate + unlabeled lactate). The FE of lactate in the medium was 76 ± 1%, 65 ± 2% and 84 ± 1% in the HK2, UMRC6 and UOK262 cells, respectively. This implies that the predominant source of lactate in these cells is glucose, although there is a contribution from other carbon sources as well. The intracellular concentration of 13C lactate was also significantly higher in the UOK262 cells compared to the UMRC6 or the HK2 cells (p<0.05). The intracellular FE of lactate was 62.5 ± 3.1%, 61.8 ± 1.5% and 78.6 ± 0.4% in the HK2, UMRC6 and UOK262 cells, respectively. The differential lactate FE in the intracellular compartment and the medium might be related to lactate compartmentalization in the cells. Such compartmentalization has been reported to exist in the brain and myocardium (39, 40). It is possible that one compartment of intracellular lactate originates predominantly from 13C labeled glucose, and the subsequently labeled lactate is preferentially exported into the medium. Another compartment of lactate may derive from other sources such as from glutamine via glutaminolysis (41), and this compartment of lactate may not be as readily exported into the medium as that from glucose. The presence of lactate compartmentalization may also in part explain the higher FE of intracellular lactate in the UOK262 cells compared to the other cells. Because UOK262 have FH mutation with reduced TCA cycle metabolism, they are more likely to produce lactate from glycolysis than from other pathways such as glutaminolysis that contains parts of the TCA cycle. This may explain the higher FE of the intracellular lactate from labeled glucose in the UOK262 cells. Taken together, the above findings confirmed that UOK262 cells are highly glycolytic with increased production of lactate. Interestingly, the 13C lactate concentration was lower in the UMRC6 RCC cells relative to both HK2 and UOK262 cells. This was in agreement with the steady state
intracellular lactate concentration data, which also showed a decreased lactate pool in UMRC6 cells compared to the other two cell lines (Figure 1b).

Hyperpolarized $^{13}$C MRS demonstrates higher real-time pyruvate-to-lactate flux in RCC cells compared to normal HK2 cells, but lower pyruvate-to-lactate flux in the metastatic UOK262 cells than the localized UMRC6 cells

Given the dynamic nature of cellular metabolism, we then investigated the real-time pyruvate metabolism in the 3 cell lines utilizing HP $^{13}$C MR. We performed our HP $^{13}$C MR experiments using a bioreactor, a continuously perfused 3D cell culture system that provides a controlled and physiological setting for the cells. This system has been shown to produce highly reproducible HP MR data (28), and facilitates the characterization of hyperpolarized substrate to metabolite conversion. $^{31}$P MR spectroscopy was employed to monitor changes in cell bioenergetics during the bioreactor studies. Representative $^{31}$P spectra of the cells are shown in supplementary data (Figure S1). NMR signals for the nucleoside triphosphates (NTPs: $\gamma$NTP, $\alpha$NTP, and $\beta$NTP), phosphocholine (PC), inorganic phosphate (P$_i$), and glycerol phosphocholine (GPC) were readily visible. The total NTP content was unchanged following the injection of HP $^{13}$C-pyruvate, indicating maintenance of cell viability during the course of the HP experiments. Figure 3 shows the PC/GPC ratios and PC+GPC concentration in the 3 cell lines. We found significantly higher PC+GPC concentration in the UMRC6 cells compared to the UOK262 cells ($p<0.05$), which was in agreement with the steady state $^1$H data from 2D cell culture. In addition to monitoring cell energetics, $^{31}$P spectroscopy also enables quantitative HP data analysis by normalizing the HP MR data with respect to the number of viable cells, through concomitant measurements of $\beta$NTP concentration via $^{31}$P MRS.

Figure 4a illustrates the scheme of $^{13}$C labeled carbon atom transitions used to detect $^{13}$C-pyruvate metabolism during the HP MR experiment. After the injection of HP $^{13}$C-pyruvate into the bioreactor, the real time pyruvate-to-lactate flux was assessed for all three cells lines.
HP pyruvate MR in renal cell carcinoma cells

The data were fit to a two-state model of interconversion of pyruvate to lactate and the metabolic fluxes were calculated (28). Figure 4b shows fitted pyruvate-to-lactate flux and representative spectra of $^{13}$C-pyruvate and lactate. The average fluxes, at a flow rate of 2.5ml/min in the bioreactor, for each of these cell lines are demonstrated in Figure 4c. The observed flux rate was significantly higher in the two RCC cell lines (UMRC6 and UOK262) as compared to the renal tubule cell line HK2 (UMRC6 vs. HK2 p<0.0001, UOK262 vs. HK2 p=0.003). Unexpectedly, the observed real time HP pyruvate-to-lactate flux for UOK262 cells (representative of metastatic RCC) was lower than that of the UMRC6 cells (representative of localized RCC). Similar to the flux data, the area under of the curve for the $^{13}$C lactate was higher in the RCC cells than the normal renal tubule cells, but was lower in the UOK262 RCC cells than the UMRC6 RCC cells (supplemental data Table S1). Additional analysis of hyperpolarized $^{13}$C dynamics of the cells perfused in the bioreactors was summarized in Table S1.

mRNA expression analysis demonstrates increased monocarboxylate transporter 4 (MCT4) in the metastatic UOK262 cells

To better understand the cellular processes underlying the HP pyruvate flux results, we then assayed the mRNA expression and enzyme activity level of LDHA, and the mRNA expression of MCT1 and MCT4 in the 3 cell lines. LDHA encodes the predominantly M isoform of LDH, which catalyzes the conversion between pyruvate and lactate. MCT1 mediates the pyruvate transport into the cells, and MCT4 mediates the efflux of the lactate out of the cells (42). We found that the mRNA expression of LDHA was significantly higher in the UOK262 cells than the other two cell lines (Figure 5). For the LDH activity, $K_m$ of the two RCC cell lines was significantly higher than that of the HK2 cells ($p<0.03$), but not significantly different between the UMRC6 and UOK262 RCC cells. The Vmax of UOK262 cells was significantly higher than that of HK2 cells ($p<0.05$). The mRNA expression of MCT1 was significantly higher in the UMRC6
cells (UMRC6 vs. HK2, p=0.0004; UMRC6 vs. UOK262, p=0.0002) while the MCT4 expression was significantly elevated in the UOK262 cells (UOK262 vs. HK2, p=0.001; UOK262 vs. UMRC6, p=0.02).

The higher HP pyruvate-to-lactate flux in UMRC6 cells, as compared to UOK262, was likely due, in part, to the higher MCT1 expression rather than the lactate pool size in the UMRC6 cells, as both the steady-state and 24 hour labeling data showed lower lactate pool size in the UMRC6 cells (Figure 1b and Figure 2e). Importantly, the differential expression of MCT4 may explain the apparent discrepancy between the real time HP pyruvate-to-lactate flux and the 24-hours labeling of lactate in the UOK262 cells compared to the UMRC6 cells. The UOK262 cells have an almost two-fold higher MCT4 expression compared to the UMRC6 cells, suggesting that they likely have more rapid MCT4-mediated export of lactate out of the cells. Rapid lactate efflux is essential for maintaining a neutral intracellular pH, and a high rate of glycolysis and lactate production over time. In contrast, UMRC6 cells have lower MCT4 expression, and likely slower rate of lactate export. Although UMRC6 cells have higher MCT1, these cells would be less able to maintain a high rate of lactate production over time due to buildup of intracellular lactate. Therefore, while the real time flux of pyruvate to lactate during the timeframe of the HP experiment was lower in the UOK262 cells than the UMRC6 cells, the higher MCT4 expression in the UOK262 cells likely resulted in more rapid lactate efflux and accounted for the significantly higher $^{13}$C labeled lactate accumulated in the medium in the 24-hour labeling experiment. Over time, the large amount of labeled lactate accumulated in the medium of UOK262 cells likely diffused back into the cells down a gradient, and may explain the higher intracellular labeled lactate in the UOK262 cells compared to the UMRC6 cells. We postulate that, while such diffusion of lactate back into the cells may reduce further generation of labeled lactate, this process occurs after a large amount of lactate has already accumulated in the medium of the UOK262 cells. This accumulation of medium lactate and diffusion back into the
UOK262 cells were likely accentuated in the 2D cell cultures where the extracellular lactate was not removed, in contrast to the bioreactor where the medium was continuously exchanged.

It is also important to note that while MCT1 may affect the HP lactate signal (both the intracellular and extracellular HP lactate) if it were the rate-limiting step in the pyruvate-to-lactate flux, the relative proportion of the intracellular versus extracellular HP lactate would be determined by MCT4, which modulates the lactate efflux. Additionally, lactate efflux in general is not expected to be significantly affected by MCT1, since most of the lactate produced in the cells is derived from glucose (transported via GLUT1) rather than pyruvate (transported via MCT1) uptake into the cells.

**Hyperpolarized $^{13}$C-pyruvate MR combined with flow rate modulation in the bioreactor demonstrate rapid efflux of lactate in the metastatic UOK262 cells**

We then performed a second set of HP MR experiments using different flow rates in the bioreactor in order to investigate the real-time lactate efflux rate in the two RCC cell lines. At high flow rates, the extracellular lactate will more likely flow out of the NMR coil’s sensitive volume and will not contribute to the MR signal, thereby decreasing the observed pyruvate-to-lactate flux ([Figure 6a](#)). It follows that the relative amount of extracellular lactate (lactate in the medium) of the two RCC cell lines, which reflects the lactate efflux rate, can be inferred from the observed HP pyruvate-to-lactate flux at different flow rates. [Figure 6b](#) shows the pyruvate-to-lactate flux at different flow rates for the two RCC cells. For the UMRC6 cells, the mean observed HP pyruvate-to-lactate flux was 0.92 nmol/s per $10^6$ cells at 1.3 ml/min, 0.90 nmol/s per $10^6$ cells at 2.5 ml/min, and 0.94 nmol/s per $10^6$ cells at 3.8 ml/min, all of which were not statistically different from one another. For the UOK262 cells, the mean observed HP pyruvate-to-lactate flux was 0.56 nmol/s per $10^6$ cells at 1.3 ml/min, 0.51 nmol/s per $10^6$ cells at 2.5 ml/min, and 0.41 nmol/s per $10^6$ cells at 3.8 ml/min. These observed HP pyruvate-to-lactate flux for the UOK262 cells progressively decreased at higher flow rate, with a significant 20%
HP pyruvate MR in renal cell carcinoma cells

decrease in the flux between the 2.5ml/min and 3.8ml/min flow rate (p=0.01). At the high flow rate of 3.8ml/min, the decreased pyruvate-to-lactate flux in the UOK262 cells indicated that these cells had more rapid lactate efflux and higher amount of extracellular lactate, which was readily removed from the NMR-sensitive region at high flow rate. The high flow rate should not have significantly limited the MCT1-mediated pyruvate uptake into the cells. This is because the injected HP pyruvate substrate available to the cells was expected to be in excess compared to MCT1, even at the high flow rate of 3.8ml/min. Indeed, the UMRC6 cells, with two-fold higher expression of MCT1 compared to the UOK262 cells, showed similar HP pyruvate-to-lactate flux at all 3 flow rates, indicating that the flow rates did not limit pyruvate uptake. The flow rate should also not have affected the enzymatic conversion of pyruvate to lactate in the cells. Taken together, the HP flux data at different flow rates strongly support the notion that the UOK262 cells have increased MCT4-mediated lactate efflux out of the cells.

Additionally, we incubated the UMRC6 and UOK262 cells for 2 hours in medium containing [3-13C] pyruvate, and observed 0.47 ± 0.05 versus 2.32 ± 0.27 μmols/10⁶ cells of 13C labeled lactate in the medium of UMRC6 versus UOK262 cells. This > 5-fold increase in the extracellular lactate of the UOK262 cells further verifies that lactate derived from labeled pyruvate is produced and transported out of the cells at a higher rate in the UOK262 cells compared to the UMRC6 cells.

Discussion

There is increasing evidence that RCCs are among those tumors strongly linked to abnormal metabolism, a feature that may be exploited therapeutically. In this work, we investigated the pyruvate metabolism in perfused human RCC cells using a clinically translatable HP 13C MR probe, and interrogated both the biochemical basis of the observed HP MR data and its relationship to cancer aggressiveness. We found higher pyruvate-to-lactate flux, consistent with increased glycolysis, in RCC cells compared to normal renal proximal
HP pyruvate MR in renal cell carcinoma cells

tubule cells. We further noted that a key feature distinguishing the localized UMRC6 from the metastatic UOK262 RCC cells is the lactate efflux rate, and that, importantly, this feature can be noninvasively depicted via real-time monitoring of HP $^{13}$C-pyruvate-to-lactate flux.

Lactate efflux is predominantly mediated by MCT4, which is a proton-coupled lactate transporter (42), exporting lactate and H+ in the same direction out of the cells. Rapid lactate efflux serves to maintain high levels of glycolysis in cancer cells, and concurrently acidifies the extracellular environment (11). Low extracellular pH supports invasion and metastasis, perhaps due to pH-dependent activation of cathepsins and metalloproteinases that degrade extracellular matrix and basement membranes (43). In this study, we found that the metastatic UOK262 cells have significantly higher MCT4 expression compared to the localized UMRC6 cells, and also have more rapid export of lactate out of the cells. UOK262 cells have mutations in the TCA enzyme FH, which leads to an uncommon and highly aggressive hereditary RCC. However, recent studies have shown that FH mRNA and protein expression are reduced in clear cell RCC, the most common histological variant of kidney cancer, promoting tumor migration and invasion (44). The reduced FH leads to accumulation of hypoxia inducible factor-2 alpha (HIF-2α) (45), a transcription factor known to promote renal carcinogenesis in part by up-regulating glycolysis (17). Thus, the metabolic changes observed in the UOK262 cells are likely not unique to this particular RCC type, and the MCT4-mediated lactate efflux may be an important determinant of RCC aggressiveness in general. Supporting this hypothesis, a recent study showed that MCT4 protein expression in primary clear cell RCCs was associated with poorer relapse-free survival, and correlated with Fuhrman nuclear grade (46). Additionally, MCT4 knockdown RCC cell lines had reduced intracellular pH, impaired proliferation and increased apoptosis (46). These studies indicate that MCT4 targeting may also be an important strategy for the treatment of RCCs.

We showed that the MCT4-mediated lactate efflux in living cells can be explored noninvasively using HP $^{13}$C MR. This was accomplished by monitoring the real time cellular
HP pyruvate MR in renal cell carcinoma cells

Pyruvate-to-lactate fluxes under different flow rates in the bioreactor. While our study utilized an ex vivo system, interrogation of lactate export using HP $^{13}$C MR can be achieved in vivo. For example, it is possible to measure the tumoral extracellular or interstitial pH, which in part reflects the amount of exported lactate, using HP $^{13}$C bicarbonate MR (47, 48). Moreover, it is possible to discriminate the local environment of HP metabolites using diffusion weighting in vivo (49, 50). Future studies will develop diffusion-weighted HP MR that can directly quantify the relative amount of intracellular versus extracellular lactate.

While total lactate levels can also be monitored using $^1$H MRS, this approach has limited utility in the metabolic evaluation of renal tumors, particularly in the in vivo setting. Lactate and lipid peaks usually overlap such that the assessment of lactate is challenging even when methods for lipid suppression are applied. More importantly, the real time metabolic fluxes, influenced by enzymatic and transporter expression, cannot be captured using $^1$H MRS.

In conclusion, we have demonstrated that HP $^{13}$C-pyruvate MRS enables real-time observation of differential lactate efflux, mediated by MCT4, in living RCC cells of varying aggressiveness. Importantly, as MCT4 and lactate efflux are implicated in the pathogenesis of many types of cancers, HP $^{13}$C MRS has the potential to noninvasively interrogate tumor aggressiveness and treatment efficacy in a broad range of cancers.

Grant Support: This work was supported by NIH P41EB013598 (to JK), R01CA166766 (to DMW), K99EB014328 (to KRK), Department of Defense Peer Reviewed Cancer Research Concept Award (to ZJW), Radiological Society of North America Scholar grant (to ZJW).
HP pyruvate MR in renal cell carcinoma cells

References

HP pyruvate MR in renal cell carcinoma cells


**Figure legends**

**Figure 1.** Steady state major metabolites in the 3 cell lines. (A) Biochemical scheme of glycolysis and tricarboxylic acid (TCA) cycle. (B) Steady state concentrations of major metabolites, as measured by $^1$H MRS, in the 3 cell lines (N=5 each). All values are reported as mean ± std. err. * denotes significant difference (p<0.05).

**Figure 2.** $^{13}$C labeled lactate in the media and intracellular compartment of the 3 cell lines following 24 hour incubation with $[1-^{13}$C] glucose. (A) Biochemical scheme illustrating $^{13}$C labeled carbon atom transitions used to detect glucose metabolism to lactate. Representative $^1$H MR spectra of metabolites in the medium (B) and intracellular compartments (C) of UOK262 following 24 hour labeling with $[1-^{13}$C] glucose. The brackets indicate the $^{13}$C satellites of each metabolite. Concentrations of $^{13}$C labeled lactate in the media (D) and intracellular compartment (E) of the 3 cell lines following incubation with $[1-^{13}$C] glucose (N=5 each). All values are reported as mean ± std. err. * denotes significant difference (p<0.05).

**Figure 3.** Phosphocholine metabolites in the 3 cell lines. PC/GPC ratios (A), and PC+GPC concentration (B) of cells encapsulated and perfused in a bioreactor (N=5 each). All values are reported as mean ± std. err. PC – phosphocholine, GPC – glycerophosphocholine.

**Figure 4.** Dynamic HP pyruvate-to-lactate flux in the 3 cell lines. (A) Scheme of $^{13}$C labeled carbon atom transitions used to detect C$_1$ labeled pyruvate metabolism during the hyperpolarized experiment. (B) Fitted pyruvate-to-lactate flux and representative spectra (inset) of $^{13}$C-pyruvate and lactate in the UMRC6 cells. (C) Comparison of observed real time HP pyruvate-to-lactate flux in the 3 cell lines at a flow rate of 2.5ml/min in the bioreactor (N=5 each). All values are reported as mean ± std. err.
**HP pyruvate MR in renal cell carcinoma cells**

Figure 5. Analysis of relevant enzyme expression/activity and transporter expression in the 3 cell lines. (A) mRNA expression of lactate dehydrogenase A (LDHA) and monocarboxylate transporters 1 and 4 (MCT1 and MCT4), relative to internal beta-actin expression, in the 3 cell lines (N=6 each). (B) LDH activity as measured by Km (μmols Pyruvate/ 10^6 cells) and V_{max} (μmols NADH/sec/10^6 cells) in the 3 cell lines (N= 6 each). All values are reported as mean ± std. err. * denotes significant difference (p<0.05).

Figure 6. Dynamic HP pyruvate-to-lactate flux in the RCC cells following flow rate modulation in the bioreactor. (A) Schematic illustrating the relationship between flow rates and observed HP pyruvate-to-lactate flux in the bioreactor. At high flow rates, the extracellular lactate will more likely to flow out of the NMR coil’s sensitive volume and will not contribute to the MR signal, thereby decreasing the observed pyruvate-to-lactate flux. The dotted square represents NMR sensitive region. O denotes encapsulated microspheres containing cells. ■ denotes extracellular lactate. (B) HP pyruvate-to-lactate flux of UOK262 and UMRC6 cells at 3 different flow rate (N=5 each). There is a decreasing trend in observed pyruvate-to-lactate flux with increasing flow rate for UOK262 cells. All values are reported as mean ± std. err. * denotes significance (p<0.05).
Figure 1

(A) Metabolic pathway diagram showing glucose metabolism and the TCA cycle.

(B) Bar graph showing concentration of various metabolites in HK2, UMRC6, and UOK262 cells.

Legend:
- □ HK2
- ■ UMRC6
- ▼ UOK262

Note: * indicates statistically significant differences.
Figure 2

(A) Schematic representation of glucose metabolism. Glucose is transported into the cell via GLUT1. Inside the cell, glucose is converted to pyruvate by the enzyme LDH. Pyruvate is then converted to lactate by another enzyme. The lactate is transported out of the cell via MCT4.

(B) Mass spectrometry analysis of extracellular glucose. The peaks represent different isotopes of glucose.

(C) Mass spectrometry analysis of intracellular metabolites. The peaks represent glutamate, alanine, and lactate.

(D) Concentration of extracellular lactate in different cell lines. The graph shows a significant increase in lactate concentration in UOK262 cells compared to HK2 and UMRC6 cells.

(E) Concentration of intracellular lactate in different cell lines. The graph shows a significant increase in lactate concentration in UOK262 cells compared to HK2 and UMRC6 cells.

* indicates significant differences.
Figure 4

A

[Diagram of metabolic pathway with isotopes and labels]

B

[Graph showing signal intensity (A.U.) vs. time (s) with peaks at specified ppm values for pyruvate and lactate]

C

[Bar graph showing HP Pyr to Lac Flux (nmol/s per 10^6 cells) for HK-2, UMRC6, and UOK262 cell lines with flow at 2.5 mL/min]

HK-2

UMRC6

UOK262

flow at 2.5 mL/min
Figure 5

A

B

LDH-A  MCT1  MCT4

Relative Expression (%)

0  5  10  15

0  1  0  20  30

H2K  UMRC6  UOK262

*  *

Km  Vmax

HK-2  UMRC6  UOK262

Author Manuscript
Published OnlineFirst on November 30, 2012; DOI: 10.1158/0008-5472.CAN-12-3461

Downloaded from cancerres.aacrjournals.org on May 29, 2017. © 2012 American Association for Cancer Research.
Figure 6

A

Low flow rate

High flow rate

Flow

B

HP Pyr to Lac Flux (nmol/s per 10⁶ cells)

Flow Rate (mL/min)

UMRC6

UOK262

*
Hyperpolarized $^{13}$C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas

Kayvan R Keshari, Renuka Sriram, Bertram L Koelsch, et al.

Cancer Res  Published OnlineFirst November 30, 2012.

Updated version  Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-3461

Supplementary Material  Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/11/30/0008-5472.CAN-12-3461.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.